Table 1.
Variables with statistical significance in univariate analysis.
| Variable | G1-Diabetic Patients N1 = 93 |
G2-Non-Diabetic Patients N2 = 246 |
p Value | OR [95% CI] |
|---|---|---|---|---|
| Age [median, IQR] | 65 (28) | 61 (21) | 0.002 | 0.97 [0.95–0.99] |
| Days of hospitalization [median, IQR] | 23 (35) | 42 (55) | <0.001 | 1.01 [1.00–1.02] |
| Days of antibiotic therapy [median, IQR] | 12 (36) | 23 (41) | <0.001 | 1.02 [1.00–1.03] |
| Number of antibiotics [median, IQR] | 2 (3) | 4 (4) | <0.001 | 1.27 [1.14–1.40] |
| Days with CVC [median, IQR] | 3 (18) | 17.50 (40) | <0.001 | 1.03 [1.02–1.04] |
| Days with UC [median, IQR] | 0 (20) | 21.50 (52) | <0.001 | 1.03 [1.01–1.04] |
| Glasgow Score [median, IQR] | 15 (8) | 10 (11) | 0.025 | 0.92 [0.86–0.99] |
| Number of antibiotics with resistance/strain [median, IQR] | 2 (8) | 8 (9) | <0.001 | 1.13 [1.07–1.19] |
| Mechanical ventilation [n, %] | 31(33.33) | 156 (63.41) | <0.001 | 0.29 [0.17–0.49] |
| Urinary catheter [n, %] | 46 (49.46) | 173 (70.33) | <0.001 | 0.41 [0.25–0.69] |
| Tracheostomy [n, %] | 18 (19.35) | 97 (39.43) | <0.001 | 0.37 [0.20–0.68] |
| Vasopressors [n, %] | 22 (23.66) | 109 (44.31) | <0.001 | 0.39 [0.22–0.69] |
| Blood transfusions [n, %] | 28 (30.11) | 132 (53.66) | <0.001 | 0.37 [0.22–0.64] |
| Nasogastric nutrition [n, %] | 33 (35.48) | 141 (57.32) | <0.001 | 0.41 [0.24–0.69] |
| Mechanical ventilation 0 h [n, %] | 62 (66.67) | 90 (36.58) | <0.001 | 3.47 [2.04–5.92] |
| Mechanical ventilation ≥ 96 h [n, %] | 29 (31.18) | 147 (59.75) | <0.001 | 0.31 [0.18–0.52] |
| Proteus mirabilis [n, %] | 75 (80.65) | 170 (69.11) | 0.034 | 1.86 [1.01–3.48] |
| Providencia stuartii [n, %] | 18 (18.35) | 76 (30.89) | ||
| Association of 2 pathogens [n, %] | 8 (8.60) | 26 (19.57) | 0.046 | 0.43 [0.17–1,07] |
| HCAI [n, %] | 30 (32.96) | 147 (59.76) | <0.001 | 0.32 [0.19–0.55] |
| Bronchial aspirate [n, %] | 10 (10.75) | 68 (27.64) | <0.001 | 0.32 [0.14–0.67] |
| Wound swab [n, %] | 51 (54.84) | 75 (30.48) | <0.001 | 3.63 [2.10–6.32] |
| Other [n, %] | 1 (1.07) | 17 (6.91) | 0.030 | 0.15 [0.00–0.96] |
| DTR phenotype [n, %] | 7 (7.53) | 72 (29.27) | <0.001 | 0.20 [0.07–0.45] |
| MDR phenotype [n, %] | 44 (47.31) | 168 (68.29) | <0.001 | 0.42 [0.25–0.70] |
| XDR phenotype [n, %] | 14 (15.05) | 91 (36.99) | <0.001 | 0.30 [0.15–0.58] |
| Aminoglycoside resistance [n, %] | 12 (12.90) | 69 (28.05) | 0.0003 | 0,38 [0.18–0.77] |
| ESBL [n, %] | 15 (16.13) | 102 (41.46) | <0.001 | 0.27 [0.14–0.52] |
| CR [n, %] | 13 (13.98) | 90 (36.59) | <0.001 | 0.28 [0.14–0.56] |
| Fluoroquinolone resistance [n, %] | 27 (29.03) | 133 (54.06) | <0.001 | 0.35 [0.20–0.60] |
Legend: N(n), number; IQR, interquartile range; CVC, central venous catheter; UC, urinary catheter; ICU, intensive care unit; h, hour; HCAI, healthcare associated infections; DTR, difficult-to-treat resistance; MDR, multi-drug resistant; XDR, eXtensive Drug Resistance; CI, confidence interval; OR, odds ratio; p, the threshold of statistical significance; CR, Carbapenem resistance; ESBL, Extended spectrum beta-lactamase.